NewsRoom Articles - Page 32 of 46

MondayNov 21, 2022 9:45 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Kicks Off First-Ever Study on DehydraTECH-CBD for the Potential Treatment of Diabetes

In November 2021, Lexaria laid out its plans for several new and ongoing R&D programs, among them hormone replacement, dementia, rheumatoid disease, and diabetesThe company has since begun its DIAB-A22-1 study program on the effectiveness of the patented DehydraTECH(TM)-processed CBD for the potential therapeutic utility against diabetesLexaria is optimistic that the study will yield some notable results, particularly with DehydraTECH-CBD having met primary safety and efficacy objectives from its HYPER-H21-4 clinical study on the potential treatment of hypertensionSo far, CBD has shown some ability to reduce the incidence of diabetes in mice, and Lexaria looks to build on these findings…

WednesdayNov 16, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) CEO Participated in The American Brain Tumor Association’s Breakthrough for Brain Tumors(R) 5K Run Following European Clinical Trial Site Activations

CNS Pharmaceuticals CEO John Climaco participated in 5K run on November 5, to show support for brain tumor patients worldwide and help raise funds for researchThe company recently announced European clinical trial site activations for its potentially pivotal global trial evaluating Berubicin for the treatment of recurring glioblastoma multiformeThe pivotal trial will study Berubicin’s results compared to the current study of care, LomustineGlobal brain tumor treatment market was valued at $2,946 million in 2022 and is expected to grow to $5,904 million by 2032 Brain and other central nervous system cancers (“CNS”) represent 1.3% of all new cancer cases in…

MondayNov 14, 2022 9:45 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Focus on Advancing Clinical Development Program for Lead Drug Candidate, Berubicin

In June 2020, CNS’ lead drug candidate, Berubicin, received Orphan Drug designation from the FDA. In June 2021, it received Fast Track designation following positive results from an extensive clinical study that saw 44% of the patients post a clinical response, with one Durable Complete ResponseWith GBM having a survival rate of only 6.8% and an average length of survival of only eight months, Berubicin is showing tremendous potential, and CNS is leading the charge to find a potential treatment option for the diseaseCNS’ management is optimistic about its lead drug candidate and continues to explore the potential treatment of…

FridayNov 11, 2022 10:30 am

Freight Technologies Inc.’s (NASDAQ: FRGT) Capacity Planning Product Poised for Tremendous Growth Following Two-Year Commitment from Shipper Partner

Freight Technologies recently announced receipt of a two-year commitment from Kimberly Clark De Mexico, SAB de CV (“KCM”), that will significantly expand its Fr8PrivateFleet productFr8Tech introduced Fr8PrivateFleet at the end of 2021 through its wholly owned subsidiary Freight App, Inc.capacity The product solves shippers’ need to secure freight over time rather than on a trip-by-trip basis and provides carriers, who can deliver the shipper’s loads based on this criterion, with a steady stream of employment opportunities and revenueThe two-year commitment is set to more than triple Fr8Tech’s capacity in the Fr8PrivateFleet product over three months Freight Technologies (NASDAQ: FRGT) (“Fr8Tech”), a…

FridayNov 11, 2022 9:00 am

Zacks SCR Uses Lexaria Bioscience Corp. (NASDAQ: LEXX) HYPER-H21-4 Study to Support $15 Share Valuation

Lexaria’s HYPER-H21-4 human clinical study was a success, producing favorable results in treating hypertension when comparing the company’s patented DehydraTECH(TM) CBD with a placeboAccording to a Zacks SCR report, the findings support their $15 share valuation of the companyZacks expects Lexaria to penetrate global markets for hypertension, nicotine delivery and antiviral productsThe hypertension drug market is expected to grow to over $34 billion through 2030, with North America anticipated to hold 35% of the market share According to the World Health Organization (“WHO”), approximately 1.13 billion people worldwide suffer from hypertension (high blood pressure), with only one in five being…

ThursdayNov 10, 2022 9:00 am

CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Maintains Strong Cash Position as It Continues Drug Development Program Pursuing Treatment for GBM

CNS Pharmaceuticals is focused on advancing its clinical development for the Berubicin drug candidate in order to bring meaningful treatment to GBM patientsGBM, which has a low survival rate, has limited treatment options when it progresses after first-line therapyThe company is looking to find a solution with Berubicin and is currently evaluating this drug candidate in a potentially pivotal global studyCNS’s ongoing R&D efforts are boosted by its strong cash position; in its Q2 2022 report, the company announced it had cash of about $9.0 million and working capital of $10.5 million CNS Pharmaceuticals (NASDAQ: CNSP), an oncology drug development…

WednesdayNov 09, 2022 10:30 am

Freight Technologies Inc. (NASDAQ: FRGT) Offers Cloud-Based Technology Solutions to Simplify Over-The-Road Trade Avenues Across USMCA Marketplace

The United States is still the world's largest economy and largest importer and exporter of goods and services – with strong ties to Mexico and CanadaMexico has reached number one as a US trade partner, with a value of $520.12 billion during the first eight months of 2022, followed by CanadaFreight Technologies’ cloud-based marketplace, Fr8App, is simplifying Over-The-Road (“OTR”) trade and reducing the carbon footprint in the industry by directly matching OTR shippers with qualified carriers and provides 24/7 live tracking, quick pay, and driver rating featuresThe company is building strategic relationships with key customers across trade industries, expanding its…

WednesdayNov 09, 2022 9:45 am

Flora Growth Corp. (NASDAQ: FLGC) Defines Path to Profitability and Portfolio Expansion with Proposed Franchise Global Health Inc. Acquisition

Flora Growth signed a definitive agreement with FGH to acquire 100% of all issued and outstanding shares by way of a statutory plan of agreementThe deal is expected to close in December following the presentation of the agreement to shareholders; the acquisition will open Flora to the German and EU medical markets, increasing the company’s international revenue and providing essential distribution to German pharmacies and a growing wholesale marketFGH’s acquisition adds to Flora’s expanding list of subsidiaries which currently comprise Vessel Brand Inc. and JustCBD, among others, and it is expected to deliver at least $3 million in annualized cost…

TuesdayNov 08, 2022 10:30 am

Lexaria Bioscience Corp. (NASDAQ: LEXX) Aiming to Address Unmet Patient Needs of Hypertensive Patients

Lexaria just completed its HYPER-H21-4 human clinical hypertension study, posting a sustained drop in blood pressure in normally active hypertensive patientsWith the success of this study, the company is working towards an IND application to seek FDA approval for its patented DehydraTECH(TM)-enabled CBD capsule formulation. 47% of adults live with hypertension but only 24% of them have it under controlWith its DehydraTECH-CBD, Lexaria hopes to not only address the severe unmet patient need associated with hypertension but also tap into a market that is set to be valued at $34 billion by 2030 Lexaria Bioscience (NASDAQ: LEXX), a global leader in…

MondayNov 07, 2022 9:00 am

Flora Growth Corp. (NASDAQ: FLGC) Agreement to Acquire Multi-national Cannabis Operator Positions Company for New Strategic Growth in Europe

Flora Growth is a cannabis cultivator and international brand developer with a strong base of operations at its licensed facility in northern ColombiaFlora recently announced its plans to acquire multi-national operator Franchise Global Health (“FGH”), the latest of its strategic acquisitions designed to boost revenues and expand Flora’s international footprintFGH is focused on the German market, where its subsidiary was the first company to sell cannabisGermany is in turn expected to provide the companies a launching pad for success in Europe, where opportunity is defined by the fact that currently Germany provides 75 to 80 percent of Europe’s cannabis salesFlora…

Spotlighting undiscovered companies with enormous upside potential.

Contact us: (512) 354-7000